IL-GE-TRANSPORTATION
18.9.2018 08:02:12 CEST | Business Wire | Press release
GE Transportation (NYSE:GE) announced today at InnoTrans 2018 a new high-speed diesel engine program, which will serve the locomotive, marine and power generation segments. The engine platform will provide improved fuel efficiency and reliability, as well as lower lifecycle costs.
“This new, high-speed engine will be a game changer for our customers,” said Dominique Malenfant, Vice President of Global Technology for GE Transportation. “They will enjoy reduced operating costs and increased availability with this engine. It will generate annual savings for customers of up to $12,000 in diesel and $4,000 in services.”
Compared to similarly sized locomotive engines, GE Transportation’s high-speed engine will offer a 5 percent better total cost of ownership. It will be 5 percent more fuel efficient, saving customers more than 6,000 gallons of diesel per year. The engine also will reduce maintenance costs by 10 percent and provide 184-day service intervals. Overhauls will be on 10-year intervals.
“We are leveraging our expertise and technology in the medium-speed engine segment to create a smaller, power-dense engine platform for products such as shunters and light-weight locomotives,” said Malenfant. “This new program will open up new segments for our business.”
The combination of a powerful engine at a smaller size and weight makes the platform ideal in regions like Asia, Africa, South America, Australia and New Zealand, which require lighter locomotives. Kazakhstan Temir Zholy (KTZ) will be the first to use the new engine to power the 300 shunter locomotives ordered earlier this year. GE Transportation will deliver the first shunter to KTZ in 2019.
“GE technology is the primary driver for developing Kazakhstan’s rail industry,” said Kanat Alpysbayev, Chairman of KTZ. “The high-speed engine will provide our new shunter fleet with the performance and maintainability needed to conduct our operations in a cost-effective manner.”
GE Transportation is developing the platform for application in multiple segments. The company is designing the high-speed diesel engine in 12- and 16-cylinder configurations with a maximum-rated horsepower of 2,500 and 3,300 respectively. At 7.40 lbs. per horsepower, the design will be 40 percent more powerful per pound compared to a medium-speed engine. It also will be digitally ready with remote prognostic capabilities to improve performance and reliability. Additionally, the engine design will meet the emission standards for both the European Union’s Stage III A/B and the International Union of Railways’ UIC Stage I/II.
The core architecture of the engine platform was jointly developed with GE Distributed Power, incorporating decades of high-speed engine experience across the Jenbacher and Waukesha product lines. GE Distributed Power is targeting a serialization of the technology to introduce a range of stationary gas engine operating potentially as soon as 2020.
Visit the GE Transportation InnoTrans 2018 webpage to learn more about this week’s announcements, demos and displays. The GE Transportation booth is located at Hall 3.2, Stand 401.
About GE Transportation
At GE Transportation , we move the world and improve the world. We are a global technology leader and supplier of equipment, services and digital solutions to the rail, mining, marine, stationary power and drilling industries. Our innovations help customers deliver goods and services with greater speed and savings using our advanced manufacturing techniques and connected machines. GE Transportation is headquartered in Chicago, IL, and employs approximately 9,000 employees worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180917005808/en/
Contact:
GE Transportation Deia Campanelli 773-297-0482 deia.campanelli@ge.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
